Brief: Evaxion Announces Positive Data For Lead Antigens In Cytomegalovirus (Cmv) Vaccine Program Evx-V1
20/11/2025 13:12
Evaxion A/S EVAX.O: EVAXION ANNOUNCES POSITIVE DATA FOR LEAD ANTIGENS IN CYTOMEGALOVIRUS (CMV) VACCINE PROGRAM EVX-V1 Source text: ID:nGNXbpx3Hv Further company coverage: EVAX.O
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma